1. Home
  2. DLNG vs FATE Comparison

DLNG vs FATE Comparison

Compare DLNG & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Dynagas LNG Partners LP

DLNG

Dynagas LNG Partners LP

N/A

Current Price

$3.89

Market Cap

140.8M

ML Signal

N/A

Logo Fate Therapeutics Inc.

FATE

Fate Therapeutics Inc.

N/A

Current Price

$2.33

Market Cap

125.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
DLNG
FATE
Founded
2013
2007
Country
Greece
United States
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
140.8M
125.6M
IPO Year
2013
2013

Fundamental Metrics

Financial Performance
Metric
DLNG
FATE
Price
$3.89
$2.33
Analyst Decision
Buy
Analyst Count
0
6
Target Price
N/A
$4.10
AVG Volume (30 Days)
52.4K
1.8M
Earning Date
05-26-2026
05-14-2026
Dividend Yield
5.18%
N/A
EPS Growth
N/A
29.88
EPS
N/A
N/A
Revenue
N/A
$6,646,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$1.10
N/A
P/E Ratio
$3.04
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.27
$0.93
52 Week High
$4.45
$3.23

Technical Indicators

Market Signals
Indicator
DLNG
FATE
Relative Strength Index (RSI) 53.02 39.37
Support Level $3.78 $2.25
Resistance Level $3.91 $2.88
Average True Range (ATR) 0.15 0.17
MACD 0.00 -0.04
Stochastic Oscillator 59.20 0.17

Price Performance

Historical Comparison
DLNG
FATE

About DLNG Dynagas LNG Partners LP

Dynagas LNG Partners LP is a limited partnership company focused on owning and operating high specification and versatile LNG carriers that are employed on multi-year contracts with international energy companies, providing the benefits of stable cash flows and high utilization rates. The company defines charters of two years or more as multi-year charters. Its current LNG Carrier fleet is optimized for trading flexibility. In addition to conventional trade, part of LNG Carrier fleet is assigned with Ice Class 1A FS notation and is winterized, which enables trade in subzero and ice bound conditions.

About FATE Fate Therapeutics Inc.

Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.

Share on Social Networks: